MAP2K7 and optic pathway glioma: Three cohorts of patients were treated with the MEK inhibitor trametinib: cohort 1 (BRAF fusion–positive LGG), cohort 2 (NF1-related optic pathway glioma), and cohort 3 (NF1-related plexiform neurofibroma).